Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine

Journal of Pediatric Infectious Diseases

Volumn 34, Issue 2, 2015, Pages 186-194

  Sobanjo ter Meulen, Ajoke ^a   Vesikari, Timo ^b   Malacaman, Edgardo A ^c   Shapiro, Steven A ^d   Dallas, Michael J ^a   Hoover, Patricia A ^a   McFetridge, Richard ^a   Stek, Jon E ^a   Marchese, Rocio D ^a   Hartzel, Jonathan ^a   Watson, Wendy J ^a   Musey, Luwy K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c MD Research   (United States)

^d Pediatric Medical Associates   (United States)

Author keywords

Immunogenicity; Pneumococcal conjugate vaccine; Safety

Indexed keywords

AMOXICILLIN; IBUPROFEN; IMMUNOGLOBULIN G; PARACETAMOL; PNEUMOCOCCUS VACCINE; BACTERIUM ANTIBODY; OPSONIN; VACCINE;

ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; LABORATORY PERSONNEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SEROTYPE; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INFANT; PATHOLOGY; PHAGOCYTOSIS;

ANTIBODIES, BACTERIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 84925451080     PISSN: 13057707     EISSN: 13057693     Source Type: Journal    
DOI: 10.1097/INF.0000000000000516     Document Type: Article

References (36)

1. Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis. 2009;48:e23-e33.
2. Song JH, Dagan R, Klugman KP, et al. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30:2728-2737.
3. Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging. 1999;15(suppl 1):21-30.
4. Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther. 2008;6:619-635.
5. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29:3398-3412.
6. O'Brien KL, Wolfson LJ, Watt JP, et al Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
7. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/ Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
8. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report. Emerging Infections Program Network. Streptococcus pneumonia. Available at: http://www.cdc.gov/abcs/reportsfindings/surv-reports.html. Accessed October 16, 2014.
9. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009;30:189-209. Accessed October 16, 2014.
10. Feikin DR, Kagucia EW, Loo JD, et al Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517.
11. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-54.
12. Elberse KE, van der Heide HG, Witteveen S, et al. Changes in the composition of the pneumococcal population and in IPD incidence in The Netherlands after the implementation of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2012;30:7644-7651.
13. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760-768.
14. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
15. Marchese RD, Puchalski D, Miller P, et al. Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol. 2009;16:387-396.
16. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004-1009.
17. World Health Organization. Recommendation for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series. No. 927, 2005
18. Yeh SH, Gurtman A, Hurley DC, et al; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
19. Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013;31:2578-2583.
20. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27:4656-4661.
21. Klein NP, Fireman B, Yih WK, et al Vaccine Safety Datalink. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126:e1-e8.
22. Blanchard-Rohner G, Pollard AJ. Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy. Expert Rev Vaccines. 2011;10:673-684.
23. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4 Pt 1):604-611.
24. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
25. Madhi SA, Klugman KP, Kuwanda L, et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009;199:1168-1176.
26. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(4 suppl):S66-S76.
27. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
28. Kieninger DM, Kueper K, Steul K, et al; 006 Study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192-4203.
29. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011;10:951-980.
30. Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine. 2011;29:9675-9683.
31. Frenck R Jr, Thompson A, Yeh SH, et al; 3011 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30:1086-1091.
32. Kanra G, Viviani S, Yurdakök K, et al. Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine. Pediatr Int. 2003;45:314-318.
33. Wuorimaa T, Dagan R, Väkeväinen M, et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis. 2001;184:1211-1215.
34. Wuorimaa TK, Dagan R, Bailleux F, et al. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Vaccine. 2005;23:5328-5332.
35. Puumalainen T, Dagan R, Wuorimaa T, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J. 2003;22:141-149.
36. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207-7211.